4
Changes in Ownership
Atara Biotherapeutics, Inc. Filed Acc 0001209191-17-061621
EVP & Chief Strategy Officer sold 7,000 shares at $15.00 ($105,000)
- EVP & Chief Strategy Officer acquired 4,146 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
Table I: Non-derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Soffer Gad EVP & Chief Strategy Officer | 2017-11-15 | Option exercise | +4,146 | 263,236 | D: show line 1 in the form | ||
| Soffer Gad EVP & Chief Strategy Officer | 2017-11-17 | Sale | −7,000 | $15.00 | $105,000 | 256,236 | D: show line 2 in the form |
| Open-market sales · 7,000 sh · avg $15.00 · $105,000 | |||||||
Table II: Derivative
| Insider | Date | Transaction | Shares | Price | Value | Exercise | Expires | Underlying | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|
| Soffer Gad EVP & Chief Strategy Officer | 2017-11-15 | Option exercise · Restricted Stock Units | −4,146 | 2,764 | D: show line 3 in the form |
Loading xslF345X03/doc4.xml…